EIR Brochure Final 2 Paperturn - Flipbook - Page 12
HOLGER HESS-STUMPP
Director, Strategic Alliance Manager
Bayer
DAVID REYNOLDS
CEO
AstronauTx and LoQus23
TOM OAKLEY
VP
EU Reg Affairs Propharma Group
STEVE GARDNER
CEO & CO-Founder
PrecisionLife
Holger Hess-Stumpp worked as a
molecular and cellular biologist at
the German Cancer Research Center
Heidelberg and is now 25 years with
Bayer AG. He has a long-term
expertise in drug discovery, mainly
for oncology targets. In this regard
he was responsible as a lab head and
later as a department head for in
vivo experimental tumor models and
many different topics such as
chromatin modulation, cell cycle,
anti-angiogenesis and tumor
metabolism
David is currently the CEO of two
Dementia Discovery Fund-created
companies, AstronauTx and
LoQus23. Prior to that David was
the CFO of Alzheimer's Research
UK, Europe's largest dementia
research charity investing in
translational drug discovery. He has
held a variety of R&D leadership
roles with responsibilities ranging
from exploratory biology, drug
discovery, early clinical and business
development.
Tom has a DPhil from the
University of Oxford and has
worked in EU regulatory affairs
for 15 years, supporting the
development of new medicines,
mostly for the treatment of
cancer or rare disease. Tom leads
an EU regulatory consulting
group, where he supports biotech
companies with everything they
need in order to navigate the EU
and UK regulatory environments,
though to obtaining a marketing
authorisation.
Steve is a serial entrepreneur with
over 25 years’ experience developing
and commercializing ground-breaking
data science and informatics in the
healthcare, life sciences and agrifood sectors. Never afraid to
innovate, Steve has an established
track record in building world-class
companies in the UK, EU and US.
Steve has held CxO positions in
several international businesses,
supplying innovative computational
biology, chemistry and semantic data
integration tools.
Holger can advise on:
Drug discovery and
development.
Oncology.
Industry engagement
strategies.
Routes to progress
translational projects.
David can advise on:
Small molecules drug
discovery.
Therapeutic areas of pain
and neuroscience.
Routes to progress
translational projects.
Careers development for
early careers researchers.
Tom can advise on:
Clinical development
requirements and gaining
authorisation for clinical
trials.
Scientific advice.
Paediatric requirements.
Incentives such as orphan
designation.
Steve can advise on:
Data science & informatics in
healthcare.
Start-up creation and
identify commercial
opportunities.
Routes to progress
translational projects.